SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is facing intense investor scrutiny following its recent earnings report, with the stock experiencing significant after-hours volatility despite an earnings beat. Community sentiment is largely divided, balancing the long-term strategic potential of the proposed Warner Bros. Discovery acquisition and its associated intellectual property against concerns over a pause in share buybacks and a cautious outlook. Discussions are heavily focused on whether current price levels represent a significant buying opportunity or signal further downside amidst an evolving competitive streaming environment.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

ProShares Ultra Bloomberg Natural Gas ($BOIL) is experiencing a major surge as extreme cold weather forecasts, including polar vortex threats, fuel expectations for significantly increased natural gas demand across the US. The community is buzzing with predictions of a massive short squeeze, though some caution about the inherent volatility and historical patterns of natural gas's rapid movements.

Lynas Rare Earths Ltd. engages in the production of rare earth minerals. It focuses on the exploration, development, mining, and processing of rare earth deposits. The company was founded by Nicholas Anthony Curtis on May 23, 1983 and is headquartered in Perth, Australia.

Lynas Rare Earths Limited

Lynas Rare Earths is gaining significant attention following its strategic partnership with Noveon Magnetics to establish a domestic U.S. supply chain for rare earth permanent magnets, a move strongly supported by broader geopolitical initiatives to reduce reliance on foreign supply. The community is keenly anticipating the upcoming quarterly results for further insights, viewing Lynas as a crucial player positioned to benefit from the tightening global rare earths market amidst increasing demand and strategic government focus on critical minerals.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending due to highly positive Phase 1 clinical trial data for its oral eczema drug, soquelitinib, which showed significant skin improvement and a favorable safety profile, even in patients resistant to other therapies. The community is buzzing about its potential as a game-changer in a large market, leading to speculation about future partnerships or a buyout, though some are anticipating a potential share offering following the rapid appreciation.

Anteris Technologies Global Corp. is a structural heart company, which engages in the development and commercialization of medical devices for heart diseases. It operates through the following geographical segments: United States, Germany, Australia, Switzerland, and Sweden. The company was founded in 1999 and is headquartered in Eagan, MN.

Anteris Technologies Global Corp.

Anteris Technologies Global

Anteris Technologies Global (AVR) is trending following news of a strategic private placement with Medtronic and the enrollment of the first patients in its global pivotal PARADIGM trial for the DurAVR heart valve. The community is actively discussing the validation from Medtronic's investment and the significant milestone of advancing its core product, with many believing the stock remains undervalued despite recent share offerings.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending amidst significant downward pressure, pushing its RSI to historically oversold levels reminiscent of major market downturns and sparking intense debate among traders. While many in the community point to technical breakdowns and broader geopolitical concerns, others anticipate a sharp rebound ahead of upcoming earnings, citing strong iPhone demand and a strategic AI roadmap. This creates a sharply divided sentiment on whether the current dip is a buying opportunity or signals further downside.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is trending due to a significant sell-off in the broader software sector, driven by pervasive investor concerns about AI's disruptive impact on traditional SaaS models. Community sentiment is sharply divided, with some fearing AI will make CRM obsolete while others strongly believe its deep data moat and integrated AI solutions, like Agentforce, position it for long-term growth. This divergence has led many to view the current valuation as an irrational overreaction, presenting a compelling accumulation opportunity.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is at the center of investor discussion, driven by the impending finalization of the TikTok U.S. deal, which some believe could propel its shares significantly higher due to its robust cloud and AI infrastructure backlog. Conversely, a bondholder lawsuit and considerable debt incurred for AI investments are intensifying bearish concerns, leading to a highly divided community outlook on the company's trajectory.

The Kraft Heinz Co. engages in the manufacture and market of food and beverage products. It operates through the North America and International geographical segments. The company was founded on July 2, 2015, and is headquartered in Pittsburgh, PA.

Kraft Heinz Co

Kraft Heinz is seeing heightened discussion driven by speculation surrounding Berkshire Hathaway's stake and a recent analyst downgrade, amplifying concerns about competitive pressures and declining sales. Despite these headwinds, many in the community view the current price as a "buying opportunity," citing its strong dividend, defensive sector appeal, and the potential value unlock from its planned company split and new CEO appointment.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is actively discussed amidst significant market volatility, primarily influenced by evolving geopolitical trade concerns impacting the broader tech sector. Despite recent headlines, community discussion highlights immense demand for NVIDIA's AI chips, reportedly sold out through 2027, with many investors viewing current dips as a compelling buying opportunity. This showcases an ongoing tension between macro uncertainties and NVIDIA's foundational role in the rapidly expanding AI infrastructure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Harel Insurance Investments & Financial Services Ltd. Trims Holdings in Urogen Pharma $URGN

Harel Insurance Investments & Financial Services Ltd. decreased its holdings in shares of Urogen Pharma (NASDAQ:URGN - Free Report) by 47.5% in the 3rd quarter, according to its most recent Form 13F...

Urogen Pharma (NASDAQ:URGN) Shares Down 6.5% - What's Next?

Urogen Pharma (NASDAQ:URGN) Stock Price Down 6.5% - Time to Sell...

D. Boral Capital Reiterates "Buy" Rating for Urogen Pharma (NASDAQ:URGN)

D. Boral Capital restated a "buy" rating and set a $33.00 target price on shares of Urogen Pharma in a research report on Monday...

Urogen Pharma $URGN Shares Purchased by Squarepoint Ops LLC

Squarepoint Ops LLC raised its position in Urogen Pharma (NASDAQ:URGN - Free Report) by 187.8% during the second quarter, according to the company in its most recent 13F filing with the Securities...

Urogen Pharma Target of Unusually Large Options Trading (NASDAQ:URGN)

Urogen Pharma (NASDAQ:URGN - Get Free Report) was the target of some unusual options trading activity on Wednesday. Stock investors acquired 20,427 call options on the company. This represents an...

Urogen Pharma (NASDAQ:URGN) Stock Price Up 6.4% - Still a Buy?

Urogen Pharma (NASDAQ:URGN) Stock Price Up 6.4% - Still a Buy...

Acorn Capital Advisors LLC Has $17.26 Million Stock Holdings in Urogen Pharma $URGN

Acorn Capital Advisors LLC cut its holdings in Urogen Pharma (NASDAQ:URGN - Free Report) by 16.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned...

Walleye Capital LLC Takes Position in Urogen Pharma $URGN

Walleye Capital LLC acquired a new position in shares of Urogen Pharma (NASDAQ:URGN - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange...

Entropy Technologies LP Buys New Shares in Urogen Pharma $URGN

Entropy Technologies LP bought a new position in Urogen Pharma (NASDAQ:URGN - Free Report) in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm bought...

Insider Selling: Urogen Pharma (NASDAQ:URGN) Insider Sells 10,000 Shares of Stock

Urogen Pharma (NASDAQ:URGN - Get Free Report) insider Mark Schoenberg sold 10,000 shares of the company's stock in a transaction on Wednesday, November 19th. The shares were sold at an average price...

UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.

UroGen Pharma Ltd

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.48	--	--	N/A
Q3 '25	-$0.69	-$0.69	0.34%	BEAT
Q2 '25	-$0.83	-$1.05	-25.91%	MISSED
Q1 '25	-$0.80	-$0.92	-15.10%	MISSED
Q4 '24	-$0.72	-$0.80	-11.16%	MISSED

URGN
UroGen Pharma Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest URGN News

URGNUroGen Pharma Ltd